Peptides: GHK-Cu, BPC-157, and what the research actually says

Peptides have moved from niche bodybuilding forums to mainstream wellness in the span of a few years. Social media is full of people injecting, spraying, and swallowing various peptides for skin, recovery, cognition, and longevity. The marketing has outpaced the science by a wide margin.

That does not mean the science is empty. Some peptides have interesting research behind them. But the gap between "interesting in a rat study" and "proven to work in humans at supplement doses" is vast. Here is an honest look at the most talked-about peptides right now.

GHK-Cu (Copper peptide)

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with a strong affinity for copper. It is found in human plasma, saliva, and urine. The interesting part: your GHK-Cu levels decline significantly with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60.

What the research shows

GHK-Cu has the most developed evidence base of any peptide in this article, particularly for skin and wound healing.

• Wound healing: Multiple studies show GHK-Cu accelerates wound closure, increases collagen deposition, and promotes angiogenesis (new blood vessel formation). A 2015 review documented its ability to stimulate dermal fibroblast proliferation and extracellular matrix remodeling.
• Skin remodeling: Topical GHK-Cu has been shown to improve skin elasticity, firmness, and reduce fine lines in small trials. This is the best-supported use case.
• Anti-inflammatory effects: GHK-Cu appears to modulate gene expression related to inflammation, suppressing pro-inflammatory cytokines like IL-6 and TNF-alpha in cell studies.
• Hair: Some early research suggests GHK-Cu may increase hair follicle size and stimulate growth, but the data is preliminary.

The honest assessment

GHK-Cu is one of the more credible peptides because it is endogenous (your body already makes it), has topical evidence in humans, and has a plausible age-related decline. The topical application for skin has reasonable support. Systemic use via injection is far less studied in humans.

Common forms: Topical serum (most evidence), subcutaneous injection (less evidence), oral (least evidence, likely degraded by digestion).

BPC-157 (Body Protection Compound)

BPC-157 is a 15-amino-acid peptide derived from a protein found in human gastric juice. It is the most hyped peptide in the recovery and injury community. Social media is saturated with anecdotes about tendon healing, gut repair, and injury recovery.

What the research shows

The animal data is compelling. The problem is that almost all of it is animal data.

• Gut healing: Rat studies show BPC-157 accelerates healing of various GI injuries, including inflammatory bowel disease models, fistulas, and anastomosis healing. It appears to promote angiogenesis and modulate nitric oxide pathways.
• Tendon and ligament repair: Rat and mouse studies show accelerated healing of transected tendons, with increased collagen organization and improved mechanical properties.
• Neuroprotection: Animal models suggest protective effects against various neurotoxic agents, potentially through dopamine system modulation.
• Muscle healing: Accelerated recovery from muscle crush injuries in rats.

The honest assessment

BPC-157 has an unusually large animal literature, much of it from a single research group in Croatia (Sikiric et al.). This is not disqualifying, but it means the results have not been independently replicated as widely as you might expect for a peptide this popular.

The critical gap: there are no published, peer-reviewed human clinical trials for BPC-157. None. Every recovery anecdote you read online is uncontrolled, subject to placebo effect, and confounded by the fact that injuries heal on their own.

That does not mean it does nothing. It means we do not know what it does in humans at specific doses with any scientific certainty.

Common forms: Subcutaneous injection near injury site (most common in the community), oral capsules (some evidence for gut-specific effects in animal models), nasal spray.

TB-500 (Thymosin Beta-4)

TB-500 is a synthetic version of thymosin beta-4, a 43-amino-acid peptide naturally present in nearly all human cells. It is involved in cell migration, wound healing, and new blood vessel formation.

What the research shows

• Tissue repair: Thymosin beta-4 has been studied for cardiac repair after heart attacks, showing improved cardiac function in animal models by promoting cardiomyocyte survival and angiogenesis.
• Wound healing: Promotes keratinocyte and endothelial cell migration, accelerating wound closure in animal models. Some early-stage human trials exist for topical wound applications.
• Anti-inflammatory: Reduces inflammatory markers in various animal models of tissue injury.
• Hair growth: RegeneRx (the biotech company behind clinical thymosin beta-4 research) has explored it for alopecia, with mixed results.

The honest assessment

TB-500 is often stacked with BPC-157 in the peptide community. The rationale is that BPC-157 promotes tendon and gut healing while TB-500 promotes systemic tissue repair and cell migration. This is mechanistically plausible but has never been studied as a combination in humans.

Like BPC-157, the human evidence is thin. Unlike BPC-157, thymosin beta-4 has had some formal pharmaceutical development (RegeneRx), which means there is slightly more human safety data available, though mostly from ophthalmology applications.

Epithalon (AEDG peptide)

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) designed to mimic epithalamin, a peptide extract from the pineal gland. It is marketed as a longevity peptide.

What the research shows

• Telomerase activation: A 2003 study by Khavinson et al. reported that epithalon activated telomerase in human somatic cells, potentially counteracting telomere shortening associated with aging.
• Pineal gland function: Research from the same group suggests epithalon may restore melatonin production in aging animal models.
• Lifespan extension: Some animal studies report modest lifespan increases, primarily from Russian research institutions.

The honest assessment

The longevity claims around epithalon are dramatic, and the evidence does not match. Most published research comes from a small group of researchers, primarily Khavinson and colleagues in Russia. The telomerase finding is interesting but has not been replicated by independent groups. Extending telomeres in a dish is different from extending healthy lifespan in a human.

This is the peptide where the gap between online claims and actual evidence is widest.

The regulatory situation

This is important context that most peptide content ignores.

In 2023, the FDA issued warning letters to companies selling BPC-157, and in 2024 proposed a rule that would classify several peptides (including BPC-157 and certain growth hormone secretagogues) as excluded from compounding. This means they cannot be legally produced by compounding pharmacies in the US.

GHK-Cu remains available as a topical cosmetic ingredient. TB-500 and epithalon exist in a grey area. Regulations vary significantly by country.

The quality control issue is arguably bigger than the legal one. Peptides purchased online from research chemical suppliers have no pharmaceutical quality assurance. Contamination, mislabeling, and degradation are real risks. A 2023 analysis of online peptide products found that a significant percentage did not contain the labeled amount of the active peptide.

What the peptide hype gets wrong

Anecdotes are not evidence. Someone recovering faster from a knee injury while using BPC-157 is not proof that BPC-157 healed their knee. Injuries heal. Placebo effects are powerful. The only way to know if a peptide works is controlled human trials, and for most peptides, those do not exist.

Animal doses do not translate directly. A dose that works in a 250-gram rat does not scale linearly to a 80-kg human. Allometric scaling exists, but it is not as simple as "multiply by body weight."

"Naturally occurring" does not mean "safe to inject." GHK-Cu is in your blood. That does not mean injecting it at supraphysiological concentrations is risk-free. Insulin is naturally occurring too.

What the peptide hype gets right

The mechanisms are real. BPC-157 affects nitric oxide pathways and angiogenesis in animal models. GHK-Cu modulates gene expression related to tissue repair. TB-500 promotes cell migration. These are not made-up mechanisms.

The research gap is a funding problem, not a science problem. Peptides are difficult to patent, which means pharmaceutical companies have little incentive to fund expensive human trials. The absence of human evidence is partly because nobody is paying for it.

Age-related peptide decline is real. GHK-Cu does decline with age. Thymosin beta-4 expression does change. Whether supplementing them externally reverses age-related changes is the unanswered question.

The bottom line

If you are considering peptides, the most important thing you can do is be honest with yourself about the evidence level. GHK-Cu topically for skin has reasonable support. Everything else is a bet on animal data translating to humans, taken at doses nobody has formally studied, from sources with no quality assurance.

That is not a recommendation to take or avoid anything. It is where the science stands today.

---

This article is for educational purposes only. It is not medical advice. Always consult a qualified healthcare professional before starting any new supplement or peptide regimen.